🫀 Heart, cholesterol & blood pressure

What actually decides this outcome, in order of size

This goal has an unusual property: the thing that causes the disease is measurable, cheap and almost never ordered, while the thing everybody measures is a proxy for it. Ranked by how much of the outcome each one owns:

1. Lifetime exposure to apolipoprotein-B particles, which is a number multiplied by years rather than a number. Each atherogenic particle carries exactly one apolipoprotein B, so ApoB (Apolipoprotein B) counts particles while a cholesterol result weighs their cargo. Particle count has outperformed particle number estimated other ways as a risk marker in large cohort work Epstein 2025, and the comparison between apolipoprotein B, low-density lipoprotein cholesterol and non-HDL cholesterol as risk markers has been made explicitly Sehayek 2025. Because exposure accumulates, a modest reduction begun at thirty outranks an aggressive one begun at sixty, and nothing on this page changes that arithmetic.
2. Blood pressure, which is not on this shelf and outranks most of what is. It is measurable at home for the price of one bottle of anything below, it is the input with the largest population effect, and the botanicals that touch it do so modestly: hibiscus has a systematic review with a real but small effect Ellis 2022. Measure it before you buy anything, and measure it sitting, rested, twice, on several days.
3. Lipoprotein(a), which is set at birth and tested once. It is raised in a large minority, it is essentially unresponsive to diet and training, and the reason to know it is that it changes how aggressive everything else should be. There is formal guidance on when and how to measure it Cegla 2021 and a consensus statement on what it means Kronenberg 2022. It also travels with aortic valve disease rather than only with coronary disease Shi 2026.
4. Whether your cholesterol result and your particle count agree, because in a large minority they do not. Discordance between apolipoprotein B, non-HDL cholesterol and triglycerides is documented and has implications for who is being under-treated Sniderman 2024. The people most often reassured wrongly are insulin-resistant: small particles carry less cholesterol each, so the cholesterol number looks acceptable while the particle count does not.
5. Inflammation, as a modifier rather than a target. A randomized trial selected patients by hs-CRP (High-Sensitivity C-Reactive Protein) rather than by cholesterol and still found benefit from lowering cholesterol Ridker 2008, which tells you the marker identifies risk without being the lever.
6. The compounds, last, and they divide into three unlike groups. Agents with randomized outcome data, agents with lipid data only, and agents whose lipid data has never replicated outside one group Berthold 2006. An umbrella review of lipid-lowering therapy for primary care is the honest map of the first group Dugre 2023.

The order to run these in, and what has to be true first

Measure the causal thing once, measure the modifiable thing weekly, then treat in descending order of evidence quality. The sequence below is not evidence-tier ranking; it is what has to be known before the next step means anything.

1. One requisition, once, that includes the test nobody orders. Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B), Lipoprotein(a) — Lp(a), hs-CRP (High-Sensitivity C-Reactive Protein), HbA1c (Hemoglobin A1c) and Comprehensive Metabolic Panel (CMP). Lipoprotein(a) goes on this one because it is a once-in-a-life measurement and because knowing it changes the target for everything else Cegla 2021.
2. Home blood pressure before any purchase. Two readings, twice a day, for seven days, and the average of days two to seven. If that average is high, the highest-value action available on this entire goal is a clinician appointment rather than a supplement, and Endothelial function & nitric oxide is where the supportive material lives.
3. Particle reduction next, because it is the arm with hard endpoints. ApoB & LDL particle reduction. The meta-analysis of individual participant data across statin trials is the reason this arm sits above the others Baigent 2010, and Ezetimibe is there because a second mechanism allows a lower dose of the first.
4. Then the endothelium, which is where most of the botanical evidence actually is. Endothelial function & nitric oxide holds Beetroot (Nitrates), Cocoa Flavanols, Citrulline Malate and Pycnogenol. This arm improves a function you can measure and has far less outcome data than the arm above it, which is a reason to sequence it second rather than a reason to skip it.
5. Then residual risk, if lipoprotein(a) came back raised or there is a family history that the panel does not explain. Thrombosis, Lp(a) & residual risk. Non-statin options for this population have been reviewed as a group Kamanu 2025.
6. Cardiac energetics is a different patient. Cardiac energetics & heart failure support is written for a failing heart, and CoQ10 and D-Ribose were trialed in that population rather than in a tired one.
7. Venous disease is a different tissue entirely. Venous & microcirculation holds Diosmin, Horse Chestnut and Butcher's Broom. Heaviness, varicosities and edema are a valve and vessel-wall problem, not an atherosclerosis problem, and treating one with the other is the commonest category error on this goal.

What gets bought for this that cannot move it

The category that fails structurally is anything sold on a lipid number without an outcome behind it. This is the goal where the distinction is not academic, because the field ran the experiment: agents that improved several lipid fractions at once have failed to improve events when added on top of adequate particle reduction, and the current review of non-statin options is written around exactly that history Kamanu 2025. A supplement that lowers a cholesterol fraction has demonstrated that it lowers a cholesterol fraction. Niacin (Flush) is the case worth knowing by heart.

The single-source result is the second trap, and this goal has a textbook example. Policosanol produced large lipid effects in trials from one group and no meaningful effect when an independent group ran it Berthold 2006. Nothing about the molecule changed between those two results. Red Yeast Rice fails the other way: it works because it contains a statin, at a dose nobody controls, which makes it a worse version of a drug rather than an alternative to one.

And the reader most likely to be misdirected here is the one whose cholesterol looks fine. A normal low-density lipoprotein cholesterol with a raised particle count is a documented pattern, not a rarity Sniderman 2024, and it is the exact person a reassuring panel sends away. If the actual problem is insulin resistance, the insulin control pathway and Metabolic health & insulin sensitivity matter more than this goal does. If it is blood pressure, the answer is a prescription and a cuff. If there is chest pain on exertion, or breathlessness that is new, that is an assessment today rather than a purchase, and no page on this site is a substitute for one. Coronary calcium imaging exists for the people in between and has been used as an endpoint in supplement trials Budoff 2004, which is worth knowing before paying for a scan.

How you would know it was working, on a real read-out and a real timescale

This page makes two predictions. On an effective particle-reducing intervention ApoB (Apolipoprotein B) falls within eight weeks and stays down, and the fall is larger in percentage terms than the fall in the cholesterol number printed beside it; and Lipoprotein(a) — Lp(a), measured once, will not move for anything on this goal, which is why it is a decision input rather than a target.

• ApoB (Apolipoprotein B) with Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) at baseline, 8 weeks and 6 months. Eight weeks because hepatic receptor expression and plasma lipoprotein turnover reach a new steady state within roughly six, so an earlier draw catches the transition rather than the result. Compare the particle count against itself, since it is the number with the better risk relationship Epstein 2025.
• Lipoprotein(a) — Lp(a) once, ever, and then never again. It is genetically determined and there is guidance on interpreting a single measurement Cegla 2021. Repeating it annually generates assay noise and no information.
• hs-CRP (High-Sensitivity C-Reactive Protein) at baseline and 3 months, read as context. A raised value identifies risk that a lipid panel misses Ridker 2008. It is also raised by any infection in the preceding fortnight, so a single high result is a reason to repeat rather than to act.
• Comprehensive Metabolic Panel (CMP) at baseline and 12 weeks on any statin, and again if muscle symptoms appear. Transaminases and creatinine, and a creatine kinase only if there is pain. Ordering enzymes monthly in somebody with no symptoms generates false alarms rather than safety.
• Home blood pressure weekly, same arm, same time, seated and rested. This is the read-out with the shortest feedback loop on the entire goal and the only one that does not require a needle.

What will fool you. Triglycerides swing enormously with the last meal and with alcohol in the preceding two days, and a calculated low-density lipoprotein cholesterol inherits that swing; apolipoprotein B does not, which is part of why it is the steadier number Sehayek 2025. A large weight change alters every lipid fraction at once and will be credited to whatever was started that month. Statin muscle symptoms are real and are also frequently reproduced by placebo in blinded rechallenge, so a symptom is a reason to rechallenge rather than to conclude. And an unpurified red yeast rice product has no assay behind its monacolin content, so the dose on the label is a claim rather than a measurement.

Sources read for these sections

• Epstein E, et al. Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank. European Journal of Preventive Cardiology 2025 · PMID 40887080
• Sehayek D, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology 2025 · PMID 40681368
• Sniderman AD, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal 2024 · PMID 38700053
• Shi W, et al. Moving beyond Low-Density Lipoprotein cholesterol: apolipoprotein B and Lipoprotein (a) for sex-specific risk assessment of aortic stenosis in the UK Biobank. European Journal of Preventive Cardiology 2026 · PMID 42104638
• Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis. European Heart Journal 2022 · PMID 36036785
• Cegla J, et al. Lp(a): When and how to measure it. Annals of Clinical Biochemistry 2021 · PMID 33040574
• Baigent C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet 2010;376(9753):1670-81 · PMID 21067804
• Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008 · PMID 18997196
• Dugre N. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Canadian Family Physician 2023 · PMID 37833094
• Kamanu C. The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention. Current Atherosclerosis Reports 2025 · PMID 40172616
• Berthold HK, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.. JAMA 2006 · PMID 16705107
• Ellis LR, et al. A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers.. Nutrition Reviews 2022 · PMID 34927694
• Budoff MJ, et al. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study.. Preventive Medicine 2004 · PMID 15475033